This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

4 Companies That Are Bleeding Cash

NEW YORK ( Stockpickr) -- When it comes to corporate America, it's "survival of the fittest." Sure enough, a handful of companies get culled from the herd every year, finding their way into bankruptcy court after a brutal run of losses. For investors looking for stocks to short, it always pays to focus on these stocks. If their balance sheets keep getting weaker and weaker in the face of open-ended losses, investors tire of pouring fresh funds into them and eventually the well runs dry.

Here's a closer look at four companies that are expected to lose gobs of money in 2012. Though they may not be in deep distress in the next quarter or two, the long-term outlook will weaken further as cash balances drop.

>>5 Big Stocks to Trade for January Gains Achillion Pharmaceuticals

It's easy to take aim at biotech stocks as they are so vulnerable when it comes to cash. Take Achillion Pharmaceuticals (ACHN - Get Report) as an example. The company's ACH-1625 protease inhibitor drug holds great promise for the treatment of infectious diseases. The drug has a long way to go until it hits the market -- perhaps in 2014 or perhaps never if FDA approval is not granted.

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Meanwhile, the company likely finished the year with $70 million in cash and is burning around $15 million per quarter. That means the cash will run out in the summer of 2013, unless the company can find more access to cash. This an obvious risk with many biotechs, but you'd be surprised how many companies wait too long to replenish their balance sheets and see their stocks plunge to distressed levels.

Achillion is E+ sell by TheStreet Ratings.
1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
KIOR $0.01 -3.45%
ACHN $7.62 3.30%
SHLD $25.56 1.00%
RAD $6.17 1.30%
AAPL $110.72 -0.53%


Chart of I:DJI
DOW 16,912.29 +122.10 0.73%
S&P 500 1,995.83 +15.91 0.80%
NASDAQ 4,791.1520 +42.7910 0.90%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs